2023 Latin America Conference on Lung Cancer
JANUARY 25-27, 2023
MONTEVIDEO, URUGUAY

PROGRAM BOOK

#LALCA23
REGISTER NOW!

#TTLC23

ttlc2023.org

Learn more about virtual attendance at https://ttlc2023.iaslc.org/
Table Of Contents

Welcome Message 5
Venue Floorplan 8
Program 10
WEDNESDAY, JANUARY 25, 2023
THURSDAY, JANUARY 26, 2023
FRIDAY, JANUARY 27, 2023
Poster Listing 16
Education Awards 20
Industry Supporters & Exhibitors 22
General Information 25
Welcome Message

#LALCA23
Welcome Message

Dear Colleagues and Friends,

Welcome to the IASLC 2023 Latin America Conference on Lung Cancer taking place January 25 – 27, 2023 at the Radisson Hotel Montevideo Victoria Plaza in Montevideo, Uruguay. Lung Cancer is still the leading cause of death not only in Latin America but worldwide. Building on the success of previous Latin America Conferences on Lung Cancer (LALCA) international and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and Latin America in particular over the next few days.

With tobacco being the leading cause of morbid-mortality worldwide, the Conference will once again host a Cancer Control Program and Tobacco Forum, scheduled for Wednesday, January 25. The program will discuss important topics in lung cancer such as, but not limited to, development in surgery, radiotherapy innovations, targeted therapy, immunotherapy, and many more. We will continue with the very successful Round Table Discussions providing delegates a very unique opportunity to talk to and discuss directly with international leaders and local experts on specific topics.

We can't wait to see you all!

LALCA 2023 Meeting Co-Chairs

Luis Ubillos  
MD, PhD  
LALCA 2023 Co-Chair, Uruguay

Mario Varangot  
MD  
LALCA 2023 Co-Chair, Uruguay

Clarissa Mathias  
MD  
LALCA 2023 Co-Chair, Brazil

Carlos Barrios  
MD  
LALCA 2023 Co-Chair, Brazil

LATAM Group Co-Chairs

Luis E. Raez  
MD, FACP, FCCP  
LATAM Group Chair, United States

Edgardo S. Santos  
MD, FACP  
LATAM Group Chair, United States

Christian Rolfo  
MD, PhD  
LATAM Group Chair, United States
The current state-of-the-art in lung cancer

Register by 25 January 2023

IMPORTANT DEADLINES

17 January 2023  Abstract submission
25 January 2023  Early registration
1 March 2023     Late registration

COPENHAGEN DENMARK
29 MARCH - 1 APRIL 2023

At this year’s innovative LIVE Plus format, you will be able to review the current state-of-the-art in lung cancer therapy, update your knowledge in prevention, screening, detection and much more.

Register by 25 January 2023 and benefit from advantageous fees.
Venue Floorplan

Radisson Hotel Montevideo Victoria Plaza - 2nd Floor
Full Program

WEDNESDAY | JANUARY 25, 2023

09:00-15:00 IASLC School of Pathology
Grand Ballroom C2
09:00 Welcome Session
Chairs: Ignacio Wistuba, United States, Maria Arcila, United States

Principles and Methods: Surgical Pathology
Chair: Ignacio Wistuba, United States
09:05 Maximizing Tissue Utilization
Christina Fernandez, Chile
09:25 Choosing Best Tissue for Molecular Studies
Fabio Tavora, Brazil
09:45 Immunohistochemical Studies and FISH
Sergio Sanchez, Mexico
10:05 Discussion

Principles and Methods: Molecular Track – Tumor Tissue Testing
Chair: Ignacio Wistuba, United States
10:45 Review of Guidelines
Mercedes Liliana Dalurzo, Argentina
11:05 Molecular Studies + Technology
Isabela Werneck da Cunha, Brazil
11:25 Single Gene vs Panel vs NGS
Valeria Denninghoff, Argentina
11:45 Discussion

12:00 - 13:00 Lunch Break

Principles and Methods: Molecular Track – Liquid Biopsy Testing
Chair: Maria Arcila, United States
13:00 Plasma Testing vs Tissue
Christian Rolfo, United States
13:20 Other Liquid Biopsies – Body Fluids and Their Value
Maria Arcila, United States
13:40 Discussion

Applications - Case studies - Outlining the Latin American Experience
Chair: Maria Arcila, United States
14:00 Outline Challenges in Interpreting PDL1 Stains
Fabio Tavora, Brazil
14:10 Outline Challenges in Working with very Minimal Tumor Tissue – Low Tumor Content and Low Tissue Content
Ricardo Armisen, Chile
14:20 Outline the Use of Cell Free DNA – Limitations, Benefits
Sergio Sanchez, Mexico
14:30 Outline the Role of Evolving Biomarkers
Maria Arcila, United States
14:40 Discussion

09:15-15:00 IASLC School of Thoracic Oncology
Grand Ballroom C1
09:00 Welcome Session
Chairs: Norma Graciela Pilnik, Argentina, Edgardo Santos, United States, Luis Ubillos, Uruguay
09:15 Knowing IASLC: Why I Need to Be Part?
Heather Wakelee, United States
09:30 LATAM Activities
Luis Ubillos, Uruguay
09:45 Clinical Research in Lung Cancer: Gaps and Opportunities
Andres Cardona, Colombia
10:15 Planning a Career in Lung Cancer – Academia Practice
Norma Graciela Pilnik, Argentina
10:40 Planning a Career in Lung Cancer – Private Practice
Luis Corrales, Costa Rica
11:00 How to Become a Translational Physician
Christian Rolfo, United States
11:20 Clinical Research in the Community Setting
Luis Corrales, Costa Rica
11:35 Publish Your Research: Knowing the Process
Karen Kelly, United States

12:00 - 13:00 Lunch Break

13:00 Updating Your CV and Personal Statement
Luis Ubillos, Uruguay
13:15 Establishing a Basic Lab: Minimal Requirements
Rafael Rosell, Spain
13:30 Partnership Academia – Pharma: How to Navigate?
Edgardo Santos, United States
13:45 Radiation and Medical Oncologists Doing Research Together in LATAM: A Mirage?
Beatriz Amendola, United States
14:00 Building A Strong Thoracic Program: The Beauty of Multidisciplinary Team
Ricardo Sales dos Santos, Brazil
14:15 A Grant: How to Write and Get it?
Rafael Rosell, Spain
14:35 Wrap up and Adjourn

15:00-16:00 Living Room
Grand Ballroom C2
15:00 Diagnosing and Treating Lung Cancer in Latin America
Luis E. Raez, United States

16:00-17:00 Cancer Control Program and Tobacco Forum
Grand Ballroom C1
Chairs: Denisse Breitel, Peru, Elizabeth Ravera, United States
16:00 Implementing Interventions for Tobacco Control: Research-based Policies
Carlos Gil Ferreira, Brazil
16:15 Importance of Smoking Cessation in the Treatment of Lung Cancer Patient
Lucia Viola, Colombia
WEDNESDAY | JANUARY 25, 2023

16:30  Framework Convention in WHO in LATAM
Paulo César Correa, Brazil
16:45  Discussion

17:00-18:00  Lung Cancer Screening
Grand Ballroom C2
Chairs: Gelenis Domingo, United States, Luis Corrales, Costa Rica
17:00  Establishing Lung Cancer Screening as Standard of Care
Luis Corrales, Costa Rica
17:15  Incidental Pulmonary Programs as a Complement for Lung Cancer Screening
Lucia Viola, Colombia
17:30  Lung Cancer Screening in Latin America: Challenges and Progress
Ricardo Sales dos Santos, Brazil
17:45  Discussion
18:00-18:45  IASLC/LATAM General Meeting
Grand Ballroom C1
Chairs: Luis E. Raez, United States, Christian Rolfo, United States, Edgardo Santos, United States

19:00-19:30  Opening Ceremony
Grand Ballroom C1
Chairs: Carlos Barrios, Brazil, Clarissa Mathias, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay

19:30-20:30  Welcome Reception
Grand Ballroom C3

THURSDAY | JANUARY 26, 2023

08:30-09:30  SS.01: Diagnostic Imaging Innovation
Grand Ballroom C1
Chair: Margarita Garcia Fontes, Uruguay
08:30  EBUS and Navigation System to Yield a Diagnosis
Lucia Viola, Colombia
08:45  Robotic Bronchoscopy in Lung Cancer
Francisco Tarrazzi, United States
09:15  Discussion

08:30-09:30  SS.02: Early Career Session & Research Vision
Grand Ballroom C2
Chairs: Denisse Bretel, Perú, Christian Caglevic, Chile
08:30  How to Write a Manuscript and a Research Grant
Carlos Gil Ferreira, Brazil
08:45  How to Incorporate Research in Latin America
Carlos Barrios, Brazil
09:00  The Role of Medical School to Promote Basic and Clinical Research
Norma Graciela Pilnik, Argentina
09:15  Discussion

09:30 - 10:30  Networking Break and Poster Viewing I Grand Ballroom C3
Refreshments will be provided

10:30-11:30  SS.03: Lung Cancer Pathology in the Era of Targeted Therapy
Grand Ballroom C1
Chairs: Mercedes Liliana Dalurzo, Argentina
10:30  Tissue Quality Control for Molecular Testing
Maria Arcila, United States
10:45  New Massive Parallel Sequencing Platforms (NGS) Versus Tailored Panels (ddPCR)
Ignacio Wistuba, United States
11:00  Molecular Markers in SQCC
Alberto Chiappori, United States
11:15  Discussion

10:45-12:45  SS.05: New Developments in Surgery
Grand Ballroom C1
Chairs: Edgar Amorin, Perú, Ricardo Sales dos Santos, Brazil
11:45  Invasive Mediastinal Staging and Navigation (Mediatiinoscopy, EBUS, EUS)
Ricardo Mingarini Terra, Brazil
12:00  VATS, Robot-Assisted or Thoracotomy for Lung Cancer Surgery
Ricardo Sales dos Santos, Brazil
12:15  Sub-lobar Resection for Stage I NSCLC
Francisco Tarrazzi, United States
12:30  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairs/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-12:45</td>
<td><strong>SS.06: Adjuvant Therapy in the Molecular Era</strong></td>
<td>Grand Ballroom C2</td>
<td>Chairs: Carlos Gil Ferreira, Brazil, Ticiana Leal, United States</td>
</tr>
<tr>
<td>11:45</td>
<td>Prognostic and Predictive Markers for Adjuvant Therapy NSCLC</td>
<td></td>
<td>David Carbone, United States</td>
</tr>
<tr>
<td>12:00</td>
<td>Targeted Agents in the Adjuvant Setting</td>
<td></td>
<td>Edgardo Santos, United States</td>
</tr>
<tr>
<td>12:15</td>
<td>Immunotherapy in Lung Cancer Adjuvant Setting</td>
<td></td>
<td>Claudio Martin, Argentina</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td><strong>Lunch Break</strong></td>
<td>Grand Ballroom C3</td>
<td>Refreshments will be provided</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td><strong>Industry Symposium Sponsored by Caris Life Sciences: Upfront Broad Profiling Improves Outcomes In NSCLC</strong></td>
<td>Grand Ballroom C1</td>
<td>Welcome</td>
</tr>
<tr>
<td>13:05</td>
<td>Upfront Broad Profiling Improves Outcomes in NSCLC</td>
<td></td>
<td>Luis Raez, United States</td>
</tr>
<tr>
<td>13:30</td>
<td>Case Discussion</td>
<td></td>
<td>Edgardo Santos, United States</td>
</tr>
<tr>
<td>13:50</td>
<td>Q&amp;A with panel and audience</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-14:00</td>
<td><strong>Industry Symposium Sponsored by Varian: Truebeam Technology for the Treatment of Lung Tumors</strong></td>
<td>Grand Ballroom C2</td>
<td>Beatriz Amendola, United States</td>
</tr>
<tr>
<td>14:15-15:15</td>
<td><strong>Radiotherapy Innovations</strong></td>
<td>Grand Ballroom C1</td>
<td>Chair: Arthur Accioly Rosa, Brazil</td>
</tr>
<tr>
<td>14:15</td>
<td>SBRT for Oligometastatic Disease</td>
<td></td>
<td>Beatriz Amendola, United States</td>
</tr>
<tr>
<td>14:30</td>
<td>Role of SBRT in Early Stage NSCLC</td>
<td></td>
<td>Gustavo Sarria, Perú</td>
</tr>
<tr>
<td>14:45</td>
<td>High Technology in Radiation Therapy, Potential Indications, and Benefits in Lung Cancer</td>
<td>Ana Botero, United States</td>
<td></td>
</tr>
<tr>
<td>14:15-15:15</td>
<td><strong>Combined Modality Therapy</strong></td>
<td>Grand Ballroom C2</td>
<td>Chairs: Gustavo Ferraris, Argentina, Tannia Soria Samaniego, Ecuador</td>
</tr>
<tr>
<td>14:15</td>
<td>Combining Radiation Therapy with Targeted Therapy in Oligometastatic Disease</td>
<td></td>
<td>Andres Cardona, Colombia</td>
</tr>
<tr>
<td>14:30</td>
<td>Radiation Therapy Combined With Immunotherapy for Unresectable NSCLC</td>
<td></td>
<td>Clarissa Mathias, Brazil</td>
</tr>
<tr>
<td>14:45</td>
<td>Radiation Therapy Combined with Immunotherapy as Neoadjuvant Approach</td>
<td></td>
<td>Ticiana Leal, United States</td>
</tr>
<tr>
<td>15:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15-16:15</td>
<td><strong>Networking Break and Poster Viewing</strong></td>
<td>Grand Ballroom C3</td>
<td>Refreshments will be provided</td>
</tr>
<tr>
<td>16:15-17:15</td>
<td><strong>Poster Discussion #1</strong></td>
<td>Grand Ballroom C1</td>
<td>Chairs: Luis Mas, Peru, Heather Wakelee, United States</td>
</tr>
<tr>
<td>16:15</td>
<td>PD.01.01 - Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)</td>
<td></td>
<td>Luis E. Raez, United States</td>
</tr>
<tr>
<td>16:20</td>
<td>PD.01.02 - Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)</td>
<td></td>
<td>Ana Laura Seneda, Brazil</td>
</tr>
<tr>
<td>16:25</td>
<td>PD.01.03 - Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study</td>
<td></td>
<td>Andres Cardona, Colombia</td>
</tr>
<tr>
<td>16:30</td>
<td>Posters Discussion</td>
<td></td>
<td>Rafael Rosell, Spain</td>
</tr>
<tr>
<td>16:40</td>
<td>PD.01.04 - Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population</td>
<td></td>
<td>Samuel Kareff, United States</td>
</tr>
<tr>
<td>16:45</td>
<td>PD.01.05 - Expanding Lung Cancer Education and LungMATCH, a Treatment and Trial Navigation Program, in a Culturally Sensitive Way with Nuestra Gente</td>
<td></td>
<td>Renee Botello, United States</td>
</tr>
<tr>
<td>16:50</td>
<td>Posters Discussion</td>
<td></td>
<td>Paul Bunn, United States</td>
</tr>
<tr>
<td>17:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-17:15</td>
<td><strong>Poster Discussion #2</strong></td>
<td>Grand Ballroom C2</td>
<td>Chairs: Oscar Arrieta, México, Tannia Soria Samaniego, Ecuador</td>
</tr>
<tr>
<td>16:15</td>
<td>PD.02.01 - High Extracellular Vesicle TGF- &amp; PD-L1</td>
<td></td>
<td>Diego De Miguel Perez, United States</td>
</tr>
<tr>
<td>16:20</td>
<td>PD.02.02 - Lung TS: A New 6-Gene Signature for Prediction of Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients</td>
<td></td>
<td>Leticia Ferro Leal, Brazil</td>
</tr>
</tbody>
</table>
### Thursday, January 26, 2023

#### 16:25 PD.02.03 - Alterations in the Immune Profile of LUSC and LUAD Detected by a Neural Network May Reveal New Immunotherapy Targets
Iael Weissberg, Brazil

#### 16:30 Posters Discussion
David R. Gandara, United States

#### 16:40 PD.02.04 - A Prognostic Value of 3 Gene Sets for Ever-Smokers With Non-small Cell Lung Cancer From Brazil
Isabella Lemuqui Tegami, Brazil

#### 16:45 PD.02.05 - EGFR Exon 20 Insertion Mutations in a Brazilian Lung Cancer Cohort: Challenges for the Identification and Clinical Features
Izabella Santos Negreiros, Brazil

#### 16:50 PD.02.06 - Intensified Chemo-Imuno-Radiotherapy With Durvalumab for Stage III NSCLCS: A Brazilian Single Arm Phasal Study - Pacific
William Nassib William Junior, Brazil

#### 16:55 Posters Discussion
David Carbone, United States

#### 17:05 Discussion

### Friday, January 27, 2023

#### 07:30-08:30 IASLC Women in Thoracic Oncology
Grand Ballroom C2
Chairs: Karen Kelly, United States, Clarissa Mathias, Brazil, Heather Wakelee, United States

- 07:30 Opening Remarks
  Karen Kelly, United States
- 07:35 How can We Inspire Other Women to Become Leaders?
  Heather Wakelee, United States
- 07:50 Empowering Women- What are We Achieving?
  Clarissa Mathias, Brazil
- 08:05 Panel Discussion
  Clarissa Mathias, Brazil
  Heather Wakelee, United States
  Karen Kelly, United States
  Lucia Viola, Colombia

#### 08:30-09:30 SS.11: New Developments in Targeted Therapy of Other Thoracic Malignancies
Grand Ballroom C1
Chairs: Luis Mas, Perú, Eduardo Richardest, Argentina

- 08:30 Is There a Targeted Therapy for SCLC
  William Nassib William Junior, Brazil
- 08:45 Mesothelioma: Challenges in Diagnosis and Therapeutic Outlook
  Gelenis Domingo, United States
- 09:00 Biological Insights and Novel Therapy for Malignant Thymoma
  Luis Corrales, Costa Rica
- 09:15 Discussion

#### 09:45-10:45 SS.12: Presidential Symposium
Grand Ballroom C1
Chairs: Luis Ubillos, Uruguay, Mario Varangot, Uruguay

- 09:45 PSP.01 - Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis
  Rodrigo de Oliveira Cavagna, Brazil
- 09:55 PSP.02 - Using DNA Next-Generation Sequencing in blood to Guide Therapy for Newly Diagnosed Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
  Luis E. Raez, United States
- 10:05 PSP.03 - 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients
  Aleixia Siqueira, Brazil

#### 10:30 Discussion

#### 10:45 - 11:45 Networking Break and Poster Viewing | Grand Ballroom C3
Refreshments will be provided

#### 11:45-12:45 Round Table Discussions
Grand Ballroom C1
Chairs: Clarissa Baldotto, Brazil, Eduardo Richardest, Argentina

- Table Discussion 1 - Early Stage Lung Cancer: Adjuvant Treatment
  Carlos Barrios, Brazil
  Norma Graciela Pilnik, Argentina
  Edgardo Santos, United States
January 27, 2023

Table Discussion 2 - Novel Approaches in Surgery (Robotic Surgery, VATS, Navigation System)
Ricardo Sales dos Santos, Brazil
Francisco Tarrazzi, United States
Ricardo Mingarini Terra, Brazil

Table Discussion 3 - Treatment of Wild Type Lung Cancer Tumors (First and Second Line)
Paul Bunn, United States
Carlos Carracedo, Perú

Table Discussion 4 - Therapy of Tumors Carrying EGFR Mutations
Luis Corrales, Costa Rica
Karen Kelly, United States
Rafael Rosell, Spain

Table Discussion 5 - ALK Positive Tumors: Therapies
Rossana Ruiz, Perú
Ticiiana Leal, United States
Gelenis Domingo, United States

Table Discussion 6 - How to Study Molecular Biology and Tumor Markers
Fred R. Hirsch, United States
Ignacio Wistuba, United States

Table Discussion 7 - New Molecules and Therapies for Lung Cancer
Claudio Martin, Argentina
David R. Gandara, United States
Oscar Arrieta, México

Table Discussion 8 - Oligometastatic Lung Cancer
Beatriz Amendola, United States
Ana Botero, United States
William Nassib William Junior, Brazil

Table Discussion 9 - Diagnosis and Staging in Lung Cancer
Lucia Viola, Colombia
Luis Ubillos, Uruguay

Table Discussion 10 - Locally Advanced Lung Cancer
Luis Mas, Perú

Table Discussion 11 - Immunotherapy in Non-small Lung Cancer in Early Stage
Clarissa Mathias, Brazil
Luis E. Raez, United States

Table Discussion 12 - Liquid Biopsy
Christian Rolfo, United States
Maria Arcila, United States

Table Discussion 13 - Uncommon Oncology Drivers: ROS1, BRAF, NTRK, MMR, RET
Alberto Chiappori, United States
Andres Cardona, Colombia

Table Discussion 14 - Small Cell Lung Cancer
Elizabeth Ravera, United States
Clarissa Baldotto, Brazil
Diego Touya, Uruguay

13:00 - 14:00 Lunch Break | Grand Ballroom C3
Refreshments will be provided

14:15-16:00 SS.13: Targeted Therapy & Angiogenesis
Grand Ballroom C1
Chairs: Oscar Arrieta, México, Carlos Carracedo, Perú
14:15 EGFExon 20 and Other Uncommon Mutations
Heather Wakelee, United States
14:25 ALK Genomic Aberrations
Fred R. Hirsch, United States
14:35 cMET/BRAF/HER-2/3 Inhibitors
Paul Bunn, United States
14:45 ROS-1 Translocations
Christian Rolfo, United States
14:55 NTRK and NRG1 Fusion Proteins
Luis E. Raez, United States
15:05 New Insights of EGFR Inhibition and Mechanisms of TKI Resistance
Rafael Rosell, Spain
15:15 EGFR/ALK TKIs with Central Nervous System Penetration
Claudio Martin, Argentina
15:25 KRAS and STK11 Mutations and Co-Mutations
Alberto Chiappori, United States
15:35 Discussion

14:15-16:00 SS.14: Immunotherapy
Grand Ballroom C2
Chairs: Luis Mas, Perú, Clarissa Baldotto, Brazil
14:15 Front Line Immunotherapy Only for NSCLC: What is New?
Luis Corrales, Costa Rica
14:25 Immunotherapy Combinations No More Chemotherapy
Ticiiana Leal, United States
14:35 Immunotherapy Resistance and Agents
David R. Gandara, United States
14:45 Molecular Markers for Immunotherapy
Andres Cardona, Colombia
14:55 Immunotherapy in SQCC: The Time Has Arrived
Luis Mas, Perú
15:05 Small Cell Lung Cancer Immunotherapy
William Nassib William Junior, Brazil
15:15 Immunotherapy and Oligometastatic Disease
Karen Kelly, United States
15:25 Discussion

16:05-16:30 Closing Ceremony with Education Awards Presentations
Grand Ballroom C1
Chairs: Carlos Barrios, Brazil, Luis Ubillos, Uruguay, Mario Varangot, Uruguay
Education Awards Presentations Introducing LALCA 2024
Andres Cardona, Colombia
Tannia Soria Samaniego, Ecuador
Lucia Viola, Colombia
<table>
<thead>
<tr>
<th>Poster Listing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PP.01 - PP.17: Advanced NSCLC</strong></td>
</tr>
</tbody>
</table>
| PP.01 - Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer  
Oscar Arrieta, México |
| PP.02 - Tyrosine Kinase Inhibitor (TKI) Real-World Use in Epidermal Growth Factor Receptor Mutated (EGFRm) Advanced Non-small Cell Lung Cancer (NSCLC) Patients  
Lucía Kaminszczik, Argentina |
| PP.03 - Gender Differences in Lung Cancer in Chile  
Diego Carrillo, Chile |
| PP.04 - EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer  
Luis Mas, Perú |
| PP.05 - Access to Genomic Testing and Targeted Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Single-Institution Study  
Berénice Freile, Argentina |
| PP.06 - Real-World Study of EGFR-TKIs Combined With Radiotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer  
Yi Liu, China |
| PP.07 - Preliminary Results of a Western Mexican Cohort of Metastatic NSCLC and frequency of ALK, EGFR and PD-L1  
Mauricio de Jesús Mora Pineda, México |
| PP.08 - Analysis of the Status of Tumor-infiltrating Lymphocytes (TILS) In Patients With NSCLC  
Eduardo Richardet, Argentina |
| PP.09 - Neutrophil Lymphocyte Ratio as a Prognostic Factor in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)  
Eduardo Richardet, Argentina |
| PP.10 - Role of the Neutrophil-Lymphocyte Elationship in Patients With Advanced NSCLC Treated With Immunotherapy  
Eduardo Richardet, Argentina |
| **PP.11 - PP.17: Advanced NSCLC** |
| PP.11 - Effectiveness of Ramucirumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer Patients: a Cohort of 93 Patients  
Isabella Favato Barcelos, Brazil |
| PP.12 - Access to Molecular Testing and Factors to Implement Targeted Therapy in a Brazilian Public Health Service  
Luma Princess Schneider, Brazil |
| PP.13 - Aptamers as Novel Diagnostic Tools for Lung Cancer Detection  
Yuli Yohana Serna Torres, Brazil |
| PP.14 - Real World Data of Patients ≥ 80 Years Old With Metastatic NSCLC: Evaluation of an Underrepresented Population in Clinical Trials  
Filipe Visani, Brazil |
| PP.15 - Efficacy and Safety of PD-1 Monoclonal Antibody in the Real World  
Yaning Zhu, China |
| PP.16 - Evaluation of Pathogenicity and in Silico Analysis of HERC2 Variants in Non-Small Cell Lung Cancer  
Letícia Ferro Leal, Brazil |
| PP.17 - Stereotactic Ablative Radiotherapy in Oligometastatic Pulmonary Disease. First Institutional Experience  
Gustavo Ferraris, Argentina |
| **PP.18 - PP.26: Biology and Pathogenesis, Pathology** |
| PP.18 - Cellular Foundations of Radiotherapy Protocols Frequently Used in Pulmonary Pathology  
Gustavo Ferraris, Argentina |
| PP.19 - Methylation Profile of Non-Small Cell Lung Cancer of Brazilian Patients  
Letícia Ferro Leal, Brazil |
| PP.20 - Concordance of Actionable Mutations in Liquid Biopsies and Matched Tumor Tissue of Brazilian Non-small Cell Lung Cancer (NSCLC)  
Letícia Ferro Leal, Brazil |
**Poster Listing**

**PP.21 - Genomic Landscape of Admixed Non-small Cell Lung Cancer: A Series of Brazilian Single-Center**
Leticia Ferro Leal, Brazil

**PP.22 - Mutational Profile of Never-Smoker Patients With Lung Adenocarcinoma From a Single-Center in Brazil**
Rodrigo de Oliveira Cavagna, Brazil

**PP.23 - GALNT13 Detection in Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) Patients**
Eugenia Fernandez Armua, Uruguay

**PP.24 - High Correlation With KRAS and PDL-1 in Lung Adenocarcinoma of a Single Institution**
Bruna Motke, Brazil

**PP.25 - Quality of the Tissue Sample in the Determination of the Molecular Profile of Lung Cancer. Our Experience**
Norma Graciela Pilnik, Argentina

**PP.26 - Immunoexpression of 4 Different PD-L1 Clones in NSCLC Cases, a Comparative Study From Northeastern Brazil**
Fabio Tavora, Brazil

**PP.27 - PP.36: Early Stage NSCLC (Stage I – III)**

**PP.27 - Clinical Outcomes of Stage III Non-small Cell Lung Cancer Patients Treated With Radical Radiotherapy in a Institution in Brazil**
Denize Bodnar, Brazil

**PP.28 - Underutilization of Systemic Therapy in Patients Undergoing Pneumonectomy: A Missed Opportunity for Survival**
Jorge Humberto Rodriguez Quintero, United States

**PP.29 - Management of Lung Cancer During the COVID-19 Pandemic: Experience of a High Complexity Center in Medellin-Colombia**
Ricardo Zapata Gonzalez, Colombia

**PP.30 - Comparing the Most Influential Publications on Robotic-Assisted Pulmonary Lobectomy and on Robotic-Assisted Pulmonary Segmentectomy**
Eric Toloza, United States

**PP.31 - Marital Status Shows No Protective Effect on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy**
Eric Toloza, United States

**PP.32 - Postoperative Serum Magnesium Levels and Outcomes Following Robotic-Assisted Pulmonary Lobectomy**
Eric Toloza, United States

**PP.33 - Effect of Age on Incidences of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy**
Allison Dumitriu Carcoana, United States

**PP.34 - Impact of Cardiac Comorbidities on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy**
Allison Dumitriu Carcoana, United States

**PP.35 - Preoperative Blood-Urea-Nitrogen-to-Serum-Albumin Ratio Is Not a Predictor of Worse Outcomes After Robotic-Assisted Pulmonary Lobectomy for Lung Cancer**
Allison Dumitriu Carcoana, United States

**PP.36 - Thoracoscopic Limited Resection in Lung Adenocarcinoma, 4 Years Disease-Free Survival**
Emmanuel Peña Gomez Portugal, México

**PP.37 - PP.40: SCLC, Mesothelioma, Thymoma**

**PP.37 - Thymic Neuroendocrine RO Surgery**
Emmanuel Peña Gomez Portugal, México

**PP.38 - Unusual Location of Thymic Carcinoma and It’s Surgical Management**
Emmanuel Peña Gomez Portugal, México

**PP.39 - Helical Tomotherapy for Primary and Secondary Malignant Pleural Tumors**
Marija Jankova, Bulgaria

**PP.40 - Phase II Clinical Study: Whole-Brain Radiotherapy Plus Sequential or Simultaneous Integrated Boost for the Treatment of Brain Metastases in NSCLC**
Dai Yuan Ma, China
Poster Listing

**PP.41 - PP.44: Immunotherapy**

PP.41 - Novel Synthetic Extracellular Vesicles as a Chemotherapeutic Carrier for Potential Lung Cancer Treatment
Javiera Carrasco-Rojas, Chile

PP.42 - Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
Byoung Chul Cho, Korea

PP.43 - Retrospective Analysis of Serum Parameters in Patients Treated With Check-Point Inhibitors in 2AND Line for Advance Non-small-Cell Lung Cancer
Pablo Flores Paco, Spain

PP.44 - Immune-Checkpoint Inhibitors: Biomarkers to Predict Response to Immunotherapy in Non-small Cell Lung Cancer Patients
Katiane Tostes, Brazil

**PP.45 - PP.46: Nursing & Allied Health & Patient Advocacy & Supportive Care**

PP.45 - Understanding Therapeutic Trajectories of Adults With Lung Cancer in Chile: A Multi-Methods Study of Time to Diagnosis and Perceived Experience
Carla Campaña, Chile

PP.46 - The Impact of Multidisciplinary Teams on the Diagnosis and Staging of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Gilberto Castro Junior, Brazil

**PP.47 - PP.53: Prevention, Early Detection, Epidemiology and Tobacco Control**

PP.47 - Lacking Representation of Hispanics in Lung Cancer Screening Trials
Caio Heleno, United States

PP.48 - Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients
Diego De Miguel Perez, United States

PP.49 - Use of Ultrasound Guidance in Thoracic Surgery Biopsies in Lung Cancer
Macarena Muto, Uruguay

PP.50 - Implementation of an Institutional Lung Cancer Screening Program Using Low-Dose Computed Tomography in Argentina
María Delfina Peralta Tanco, Argentina

PP.51 - Cost-Effectiveness Study of Lung Cancer Screening in Uruguay (UY-LUNGS)
Virginia Rodriguez Sande, Uruguay

PP.52 - Current status of Lung Cancer Screening in Latin America
Lucia Viola, Colombia

PP.53 - Lung Cancer in Peru: A Disease of Never Smokers
Rossana Ruiz, Perú
Education Awards
Education Awards

Congratulations to the LALCA 2023 Education Award Winners!
Award Winners will be presented with their award during the Closing Ceremony on Friday, January 27 from 16:05 – 16:30 in Grand Ballroom C1.

Diego De Miguel Perez
Icahn School Of Medicine At Mount Sinai New York, United States

**PD.02.01:** High Extracellular Vesicle TGF-β & PD-L1 Predict Poor Outcomes in Patients With Non-small Cell Lung Cancer Undergoing Immune-Checkpoint Inhibitors

SS.10: Poster Discussion #2
Thursday, January 26 | 16:15 – 17:15
Grand Ballroom C2

Ana Laura Seneda
Faculty Of Medicine, São Paulo State University (UNESP), Brazil

**PD.01.02:** Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)

SS.09: Poster Discussion #1
Thursday, January 26 | 16:15 – 17:15
Grand Ballroom C1

Aléxia Siqueira
Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil

**PSP.03:** 12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients

SS.12: Presidential Symposium
Friday, January 27, 09:45 – 10:45
Grand Ballroom C1

Samuel Kareff
University Of Miami Sylvester Comprehensive Cancer Center/ Jackson Memorial Hospital, United States

**PD.01.04:** Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population

SS.09: Poster Discussion #1
Thursday, January 26 | 16:15 – 17:15
Grand Ballroom C1

Rodrigo de Oliveira Cavagna
Barretos Cancer Hospital, Brazil

**PSP.01:** Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis

SS.12: Presidential Symposium
Friday, January 27, 09:45 – 10:45
Grand Ballroom C1
Industry Supporters & Exhibitors

#LALCA23
The IASLC 2023 Latin America Conference on Lung Cancer would like to thank the following companies for their support:
## Industry Supporters and Exhibitors

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caris Life Sciences®</td>
<td>is the leading molecular science and technology company developing innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. <a href="http://www.carislifesciences.com">www.carislifesciences.com</a></td>
</tr>
<tr>
<td>Janssen Oncology</td>
<td>At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson &amp; Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. <a href="http://www.janssenpro.com">www.janssenpro.com</a></td>
</tr>
<tr>
<td>Seagen</td>
<td>Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. For more information visit <a href="http://www.seagen.com">www.seagen.com</a></td>
</tr>
<tr>
<td>Varian</td>
<td>At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit <a href="http://www.varian.com">www.varian.com</a> and follow @VarianMedSys on Twitter</td>
</tr>
<tr>
<td>IASLC</td>
<td>The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries. By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.</td>
</tr>
</tbody>
</table>
General Information

#LALCA23
HEALTH & SAFETY MEASURES
LALCA 2023 will be hosted as an in-person meeting. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to LALCA 2023, all necessary precautions will be taken to ensure a safe environment throughout the Conference. The following measures will be put in place to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):

VACCINATION POLICY
IASLC recommends that all in-person attendees are fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence. IASLC will, however, not require proof of vaccination prior or during the Conference.

MASKS AND FACE COVERINGS
Masks will be encouraged to be worn at LALCA 2023. By attending, you agree that:
• You have no COVID-19 symptoms
• If during your attendance you develop any COVID-19 symptoms, you will immediately:
  • Self-isolate;
  • Comply with all local/national government restrictions; and
  • Inform the LALCA 2023 Conference Secretariat by email (lalca2023-registration@icsevents.com).

IASLC and their suppliers will, in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

Please note: There will be no on-site testing facility available at LALCA 2023.

WI-FI
Network: LALCA2023
Password: LALCA2023

OPENING HOURS

Registration Desk
Foyer, 2nd Floor
Wednesday, January 25 08:00 – 19:30
Thursday, January 26 08:00 – 16:30
Friday, January 27 07:00 – 14:30

Poster Viewing & Networking
Grand Ballroom C3, 2nd Floor
Thursday, January 26 09:30 – 10:30
15:30 – 16:30
Friday, January 27 10:45 – 11:45

Exhibit Hours
Grand Ballroom C3, 2nd Floor
Wednesday, January 25 19:30 – 20:30
Welcome Reception
Thursday, January 26 09:30 – 16:30
Friday, January 27 10:30 – 14:00

ACCESS/SECURITY
Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.

LOST AND FOUND / MESSAGES
Lost and found items should be returned / claimed at the Registration Desk.
Save the Date!

Join us for WCLC 2023 in Singapore!
Abstract Submissions will open in January 2023. Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

CONNECT WITH US
@IASLC
facebook.com/IASLC
@iaslungcancer
linkedin.com/IASLC
IASLC

#WCLC23
WLCL2023.IASLC.org
IASLC 2023 Targeted Therapies of Lung Cancer Meeting
February 22-25, 2023
Santa Monica, California
#TTLC23

IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer
April 5-7, 2023
New York, New York
#SCLC23

IASLC 2023 World Conference on Lung Cancer
September 9-12, 2023
Singapore
#WCLC23

* Location and dates subject to change
Join the IASLC Today!

Scan the QR code & enter LALCAnewMember2023 to receive half off membership dues for one year.